Cytokinetics' Aficamten Gains Global Approval and Market Momentum in Heart Disease Treatment
Cytokinetics announced FDA approval of MYQORZO (aficamten), a drug for treating adults with symptomatic obstructive hypertrophic cardiomyopathy, based on positive Phase 3 trial results showing improved exercise capacity and symptoms, with safety monitored due to heart failure risk.